Skip to Main Navigation Skip to Page Content

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Diisopropylcarbodiimide: Target Organs and Levels of Evidence for GMM-10

Toxicology Study of Diispropylcarbodiimide (CASRN 693-13-0) in Genetically Modified (FVB Tg.AC Hemizygous) Mice and Carcinogenicity Study of Diispropylcarbodiimide in Genetically Modified [B6.129-Trp53tm1Brd (N5) Haploinsufficient] Mice (Dermal Studies)

Chemical (Study Title) CASRN	Peer Review Date	Route/Exposure Levels	Study Laboratory
Diisopropylcarbodiimide 693-13-0	09/28/2005	Topical Application Female Mice: 0, 4.38, 8.75, 17.5, 35, or 70 mg/kg; 10/group	BioReliance, Inc

Levels of evidence information forToxicology Study of Diisopropylcarbodiimide in Female Tg.AC Hemizygous Mice
	Female Tg.AC Hemizygous Mice
	20 Weeks
Neoplastic Lesions	None
Non-Neoplastic Lesions	None

Levels of evidence information forCarcinogenesis Study of Diisopropylcarbodiimide in Female p53 Haploinsufficient Mice
	Female p53 Haploinsufficient Mice
	27 Weeks
Levels of Evidence	No Evidence
Neoplastic Lesions	None
Non-Neoplastic Lesions	Skin: epidermal hyperplasia